Durable response achieved using Pazopanib for germ tumor cells: A case report.

Abstract

Germ cell tumors with somatic-type malignancy (GCTSTM) are rare, and patients with GCTSTM have extremely poor prognoses with a median survival of nine months. Somatic-type malignancy, which are mainly sarcomas, usually exhibit chemoresistance. The recommended therapy for GCTSTM is radical resection; however, Pazopanib, which is a multityrosine kinase inhibitor, has indicated therapeutic effects for some soft tissue sarcoma components. The current study reports the case of a 21-year-old Asian man who presented with GCTSTM after combined chemotherapy for a primary mediastinal germ cell tumor with multiple lung metastases. Despite the metastases, his disease was stable after continuous administration of Pazopanib for two years and then stopping the medication for four years. To the best of our knowledge, the current report is the first report of a durable response by Pazopanib for GCTSTM, which is a rare outcome.

• Authors: Yuta Takezawa, Hiroshi Yaegashi, Masashi Iijima, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi, Yoshihumi Kadono, Hiroko Ikeda, Atsushi Mizokami
• Journal: Molecular and clinical oncology (Mol Clin Oncol) Vol. 14 Issue 3 Pg. 48 (Mar 2021) ISSN: 2049-9450 [Print] England
• PMID: 33604038 (Publication Type: Journal Article)
• Copyright: Copyright © 2020, Spandidos Publications.